Cytokine and immunoglobulin production by PWM-stimulated peripheral and tumor-infiltrating lymphocytes of undifferentiated nasopharyngeal carcinoma (NPC) patients by Fliss-Jaber, Lilia et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Cytokine and immunoglobulin production by PWM-stimulated 
peripheral and tumor-infiltrating lymphocytes of undifferentiated 
nasopharyngeal carcinoma (NPC) patients
Lilia Fliss-Jaber1,2, Radhia Houissa-Kastally1, Kamel Bouzouita2, 
Naceur Khediri1 and Ridha Khelifa*1
Address: 1Service des Laboratoires, Hôpital Habib Thameur, Tunis, Tunisia and 2Laboratoire National de Contrôle des Médicaments, Tunis, Tunisia
Email: Lilia Fliss-Jaber - lilia.fliss@laposte.net; Radhia Houissa-Kastally - radhia.kastally@rns.tn; Kamel Bouzouita - kamel.bouzouita@rns.tn; 
Naceur Khediri - lilia.fliss@laposte.net; Ridha Khelifa* - khelifa.ridha@rns.tn
* Corresponding author    
Abstract
Background: Undifferentiated Nasopharyngeal Carcinoma (NPC) patients show a characteristic
pattern of antibody responses to the Epstein-Barr virus (EBV) which is regularly associated with
this tumor. However, no EBV-specific cytotoxic activity is detectable by the standard chromium-
release assay at both peripheral and intratumoral levels. The mechanisms underlying this
discrepancy between the humoral and cellular immune responses in NPC are still unknown, but
might be related to an imbalance in immunoregulatory interleukin production. In this report, we
investigated the ability of peripheral (PBL) and tumor- infiltrating (TIL) lymphocytes of
undifferentiated NPC patients to produce in vitro three interleukins (IL-2, IL-6, IL-10) and three
immunoglobulin isotypes (IgM, IgG, IgA).
Methods: Lymphocytes from 17 patients and 17 controls were cultured in the presence of
Pokeweed mitogen (PWM) for 12 days and their culture supernatants were tested for interleukins
and immunoglobulins by specific enzyme-linked immunosorbent assays (ELISA). Data were analysed
using Student's t-test and probability values below 5% were considered significant.
Results: The data obtained indicated that TIL of NPC patients produced significantly more IL-2 (p
= 0,0002), IL-10 (p = 0,020), IgM (p= 0,0003) and IgG (p < 0,0001) than their PBL. On the other
hand, patients PBL produced significantly higher levels of IL-2 (p = 0,022), IL-10 (p = 0,016) and IgM
(p = 0,004) than those of controls. No significant differences for IL-6 and IgA were observed.
Conclusion:  Taken together, our data reinforce the possibility of an imbalance in
immunoregulatory interleukin production in NPC patients. An increased ability to produce
cytokines such as IL-10 may underlie the discrepancy between humoral and cellular immune
responses characteristic of NPC.
Background
Undifferentiated nasopharyngeal carcinoma (NPC) is a
malignant epithelial tumor characterized by a heavy infil-
tration of non malignant lymphocytes and most of these
Published: 27 September 2004
BMC Cancer 2004, 4:68 doi:10.1186/1471-2407-4-68
Received: 17 May 2004
Accepted: 27 September 2004
This article is available from: http://www.biomedcentral.com/1471-2407/4/68
© 2004 Fliss-Jaber et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
Page 2 of 10
(page number not for citation purposes)
tumor infiltrating lymphocytes (TIL) have been shown to
be T cells [1].
The Epstein-Barr virus (EBV) is causally associated with
this malignancy since viral DNA is regularly present in the
malignant epithelial cells but not in the neighbouring
normal tissues. In addition, NPC patients show a specific
pattern of humoral responses against EBV antigens [2].
Viral proteins known to be expressed in NPC tumor cells
are the EBV-encoded nuclear antigen 1 (EBNA-1) and the
latent membrane proteins LMP-1 in 35 to 65% of cases,
and LMP-2 [3,4]. The latent membrane proteins have
been shown to serve as targets for EBV-specific cytotoxic T
lymphocytes (CTL) from normal seropositive individuals
[5,6].
Recently, CD8 positive EBV-specific cytotoxic T cell clones
were isolated from the peripheral blood and tumors of
NPC patients [7]. The majority of the isolated CTL clones
are directed towards the most immunogenic EBNA3 pro-
teins which are not expressed in NPC tumor cells. No EBV-
specific CTL activity is detectable by the standard chro-
mium release assay in NPC patients [8-10] and the activity
of any CTLs that would be present in such patients
appears to be somehow suppressed. This lack of cytotoxic
activity is in sharp contrast with the strong anti-EBV
humoral immune response seen in patients [11,12]. The
discrepancy between these two types of immune
responses in NPC is still unexplained. It has been hypoth-
esized that some viral gene products might have the
capacity to influence cytokine production in such a way as
to inhibit specific CTL activity [3,13]. Interestingly, the
product of the EBV BCRF1 open reading frame has been
found to display extensive homology with human inter-
leukin 10 [IL-10 ; [14]]. Like its human counterpart, this
viral product designated vIL-10, exerts immunosuppres-
sive functions [15]. It is postulated that IL-10 production
in malignant tumors may facilitate their escape from
immune surveillance [16].
The expression of IL-10 in NPC has been controversial.
While it has been reported that IL-10 is not expressed by
NPC cells as detected by RNA in situ hybridisation [17],
some reports using immunohistochemical and molecular
techniques showed the expression of this cytokine by epi-
thelial NPC tumor cells and TIL [18-20]. These authors
suggested IL-10 as a possible evasion mechanism against
the host antiviral system. Such a mechanism would
explain the lack of detection of EBV specific cytotoxic
activity in NPC patients at both peripheral and intratu-
moral levels [8-10,21]. Indeed, IL-10 is known to inhibit
cell-mediated immune responses [22]. IL-10 is also
known for upregulating the B cell response [23] and there-
fore, this putative mechanism is in accordance with the
strong EBV-specific humoral immune response seen in
NPC [11,12,24]. Other interleukins such as IL-2 and IL-6
may also appear to be involved in this discrepancy
between humoral and cellular immune responses due to
their central regulatory effects on T or B cells [25,26].
In this report, we investigated the ability of both periph-
eral blood lymphocytes (PBL) and TIL of undifferentiated
NPC patients to express three interleukins (IL-2, IL-6, IL-
10) and three immunoglobulin isotypes (IgM, IgG, IgA)
following pokeweed mitogen (PWM) stimulation in vitro.
The data obtained indicated some significant differences
between NPC patients and controls in interleukin and
immunoglobulin production. However, further investiga-
tions are needed to establish the relevance of these differ-
ences to the discrepancy between humoral and cellular
immune responses characteristic of NPC.
Methods
Patients and controls
17 untreated Tunisian NPC patients were included in this
study. Informed consent was obtained from all patients
before collection of blood and biopsy samples. These
patients presented for treatment at the National Cancer
Institute Salah Azaiez, Tunis or at the Farhat Hached hos-
pital, Sousse, Tunisia. Their mean age was 47,5 years
(range 25–70). All patients were diagnosed histopatho-
logically as undifferentiated NPC.
17 healthy EBV carriers who presented to donate blood at
the National Blood Transfusion Centre, Tunis, Tunisia,
were included as controls in this study.
Sera of all patients and controls were titrated for antibod-
ies directed against EBV antigens by indirect immunoflu-
orescence [27].
Lymphocyte preparations
Peripheral blood and biopsy samples were taken on the
same day from each of the 17 NPC patients. Peripheral
blood was collected from patients and healthy donors in
heparin. Mononuclear cells were isolated by centrifuga-
tion over Ficoll-Hypaque (Pharmacia) according to
Boyum [28]. Following three washes in RPMI-1640
medium (Gibco), cells were resuspended in RPMI-1640
medium supplemented with 10% heat-inactivated fetal
calf serum (FCS ; Gibco) and 50 µg/ml Gentamicin (com-
plete medium) at a concentration of 2 × 106 cells/ml.
For the preparation of tumor-infiltrating lymphocytes,
biopsies were collected from NPC tumors under sterile
conditions and immediately transferred to RPMI-1640
medium supplemented with 50 µg/ml Gentamicin. The
biopsies were washed several times in this medium andBMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
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then minced into small pieces in order to extract lym-
phocytes. The extracted cells were then washed by centrif-
ugation in the same medium and then resuspended in
complete medium at a final concentration of 2 × 106 cells/
ml.
Samples from each lymphocyte preparation were taken
for immunophenotyping by indirect membrane immun-
ofluorescence using mouse monoclonal antibodies
directed against CD3, CD4, CD8 or CD19 and FITC-con-
jugated goat anti-mouse F(ab')2 fragment. The labelled
cells were counted under a fluorescence microscope.
Stimulation by Pokeweed mitogen
PBL from healthy donors or NPC patients and TIL from
the same patients suspended at 2 × 106 cells/ml in com-
plete medium were distributed at 1 ml / well in 24-well
Costar plates. One hundred microliters of a predeter-
mined optimal dilution of PWM (Gibco), for treated
wells, or complete medium alone, for untreated controls,
were added in corresponding wells. The cells were then
cultured for 12 days at 37°C, 5% CO2 and 98% relative
humidity in a CO2 incubator. At the end of this incuba-
tion period, culture supernatants were harvested and used
for cytokine and immunoglobulin determination as
described below.
Cytokine and Immunoglobulin determination
Culture supernatants of PBL and TIL stimulated by PWM
under optimal conditions were used for both cytokine
and immunoglobulin determination by enzyme-linked
immunosorbent assays (ELISA).
IL-2, IL-6 and IL-10 concentrations were measured using
commercial sandwich-type ELISA kits (Immunotech
enzyme immunoassays, France) according to the proce-
dures described by the manufacturer.
IgM, IgG and IgA concentrations were measured using
sandwich-type ELISA assays prepared in our laboratory.
Briefly, 96 well-microplates (Greiner, Germany) were
coated for 2 hours at 37°C and overnight at 4°C with 150
µl/well of isotype-specific mouse monoclonal antibody
(Sigma, France) appropriately diluted in 0,1 M carbonate
buffer, pH 9.6. The microplates were washed four times
with phosphate-buffered saline pH 7.4 containing 0,1 %
Tween 20 (PBS-Tween), then blocked with 300 µl/well of
PBS containing 1% FCS for 30 minutes at 37°C. For the
assay, 100 µl /well of appropriately diluted culture super-
natants in PBS-Tween containing 10% FCS were incu-
bated in coated microplates for 2 hours at 37°C. The
microplates were then washed four times with PBS-Tween
and 100 µl/well of the appropriate alkaline phosphatase-
labeled conjugate (Goat anti-human IgM, IgG or IgA,
Sigma-France) were added at a 1:20000 dilution in PBS
containing 1% FCS. After a two-hour incubation at 37°C,
the microplates were washed and a p-nitrophenylphos-
phate substrate solution was added. The microplates were
incubated for 1 hour at 37°C and the reaction was
stopped with 50 µl/well of 1 N NaOH. Immunoglobulin
standards were generated using purified human immu-
noglobulins of each isotype (Sigma, France). The micro-
plates were read at 405 nm on a microplate reader (LP-
400, Diagnostic Pasteur). Data were represented as the
mean immunoglobulin concentration of triplicate cul-
tures. Immunoglobulin values were obtained by interpo-
lation from standard curves.
Statistical analysis
Data were analysed using "Student's t-test". Probability
values below 5% were considered significant.
Results
EBV serology
All patients showed a typical serological profile character-
istic of NPC as determined by indirect immunofluores-
cence. Levels of IgG antibodies to VCA were considerably
higher than those in healthy donors. Their titers varied
from 640 to 2560 (mean titer = 1065), whereas in healthy
donors such titers fluctuated between 40 and 160 (mean
titer = 70). IgG antibodies to EA were present in NPC
patients only, with titers ranging from 20 to 320 (mean
titer = 50).
Anti-VCA IgA antibodies were detected in all patients
(range : 20–320 ; mean = 61) and anti-EA IgA antibodies
were detected in only 4 patients (range : 10–80 ; mean =
27). None of the controls showed IgA antibodies against
these antigens.
Immunophenotyping of lymphocyte preparations
Immunophenotypic analysis of the lymphocyte prepara-
tions obtained from patients and controls indicated that
CD3+ lymphocytes constituted the major subpopulation
with a mean frequency of (60 ± 8)% in PBL of both
patients and controls and (55 ± 9)% in TIL. CD4+ lym-
phocytes represented (35 ± 5)% in PBL of both patients
and controls and (20 ± 3)% in TIL. CD8+ cells showed
mean values of (40 ± 6)% in PBL of patients, (36 ± 4)% in
TIL, and (28 ± 5)% in PBL of controls.
On the other hand, CD19+ B lymphocytes represented in
average (25 ± 5)% in PBL of patients, (23 ± 6)% in TIL,
and (22 ± 3)% in PBL of controls.
Cytokine production
As illustrated in Figures 1 and 2, the PBL of NPC patients
produced significantly more IL-2 (2105 ± 1152 pg/ml)
and IL-10 (1280 ± 727 pg/ml) than the PBL of healthy
donors (1286 ± 452 pg/ml, p = 0,022 for IL-2 and 793 ±BMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
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325 pg/ml, p = 0,016 for IL-10). Comparable amounts of
IL-6 were found for both groups (2375 ± 919 pg/ml for
patients and 2177 ± 435 pg/ml for controls, p = 0,429 ;
Figure 3). On the other hand, TIL of patients showed a sig-
nificantly higher IL-2 (3913 ± 1484 pg/ml, p = 0,0002)
and IL-10 (1926 ± 817 pg/ml, p = 0,02) production than
their PBL. The observed differences in mean IL-6 produc-
tion between patients'PBL (2375 ± 919 pg/ml) and TIL
(1962 ± 515 pg/ml) did not reach statistical significance
(p = 0,116).
Unstimulated lymphocytes cultured in the absence of
PWM did not show any detectable cytokine production
(data not shown).
Immunoglobulin production
The results of immunoglobulin determination showed
that the PBL of NPC patients produced significantly
higher levels of IgM (8262 ± 5315 ng/ml) than the PBL of
controls (3753 ± 2801 ng/ml, p = 0,004 ; Figure 4).
Both groups produced similar amounts of IgG (874 ± 408
ng/ml for patients and 847 ± 442 ng/ml for controls, p =
0,85 ; Figure 5) and IgA (4380 ± 4316 ng/ml for patients
and 3067 ± 2267 ng/ml for controls, p = 0,27 ; Figure 6).
On the other hand, TIL of these patients produced signif-
icantly higher levels of IgM (21162 ± 12276 ng/ml, p =
0,0003) and IgG (2789 ± 1583 ng/ml, p < 0,0001) than
their PBL. No significant differences in IgA production
were found between PBL (4380 ± 4316 ng/ml) and TIL
(6112 ± 6046 ng/ml, p = 0,34).
Unstimulated lymphocytes cultured in the absence of
PWM did not show any detectable immunoglobulin pro-
duction (data not shown).
IL-2 production Figure 1
IL-2 production. PBL and TIL from 17 NPC patients and PBL from 17 controls were cultured at a concentration of 2 × 106 
cells/ml in the presence of PWM at 1:200 dilution for 12 days. Culture supernatants were collected and assayed for IL-2.BMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
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Discussion
Previous reports indicate the absence of EBV-specific cyto-
toxic T lymphocytes detectable by the standard chromium
release assay in both the peripheral and intratumoral
compartments [8-10,21] in undifferentiated nasopharyn-
geal carcinoma. However, NPC patients show a strong
EBV-specific humoral immune response, and elevated tit-
ers of anti-EBV antibodies directed against viral antigens
are observed in their sera [11,12,24]. The mechanisms
underlying this discrepancy between humoral and cellular
immune responses in NPC patients are still unknown. It
was postulated that interleukin 10 production in
malignant tumors would facilitate their escape from
immune surveillance [16].
The expression of IL-10 in NPC has been controversial.
While some authors have reported that NPC tumor cells
do not express IL-10 [17], others observed IL-10 expres-
sion in epithelial NPC tumor cells and tumor infiltrating
lymphocytes [18,19]. They suggested such IL-10 expres-
sion as a possible mechanism for NPC tumors and EBV to
escape local cellular immune attack. Indeed, IL-10 is a
pleiotropic factor known for its suppressive effects on cell-
mediated immune responses [22]. In sharp contrast to
these inhibitory effects, IL-10 also has a potent
stimulatory effect on the humoral immune response,
inducing B lymphocyte differentiation and immunoglob-
ulin secretion [23]. Therefore, IL-10 hyperproduction
alone or in association with changes in other cytokines
might lead to an imbalance between humoral and cellular
immune responses similar to that seen in NPC.
The expression of cytokines such as IL-2 [19], IL-6 [17]
and IL-10 [18,19] in NPC has been studied mainly on
IL-10 production Figure 2
IL-10 production. PBL and TIL from 17 NPC patients and PBL from 17 controls were cultured at a concentration of 2 × 106 
cells/ml in the presence of PWM at 1:200 dilution for 12 days. Culture supernatants were collected and assayed for IL-10.BMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
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tumor biopsies using immunohistochemical and molecu-
lar techniques. To the best of our knowledge, only one
study on the ability of NPC patients'lymphocytes to pro-
duce cytokines in culture has been reported and it was
limited to IL-2 [9].
In this report, we investigated the ability of both periph-
eral blood and tumor infiltrating lymphocytes of 17
undifferentiated NPC patients to produce cytokines fol-
lowing mitogenic stimulation in culture. Since immu-
noglobulin isotypes are determined by cytokine patterns,
we also looked for possible correlations between meas-
ured cytokine levels and immunoglobulin isotypes pro-
duced. PWM was chosen to stimulate the lymphocyte
cultures because it is known to activate both T and B lym-
phocytes in humans [29,30]. In addition, the ability of
PWM to stimulate cytokine production by Tcells is similar
to that of PHA [31]. This allowed us to study the responses
of both T and B cells simultaneously in each lymphocyte
culture.
The data obtained indicate that the highest levels of IL-2
were produced by TIL cultures followed by patients'PBL.
This is in line with a report by Lakhdar et al [9] showing a
higher IL-2 production by PHA-stimulated PBL of NPC
patients than by controls. Such high IL-2 levels are
expected to favor a strong cytotoxic response since IL-2 is
needed for CTL stimulation and proliferation [32] and
they are not consistent with the known lack of detectable
CTL activity.
IL-10, a representative of the Th2 pattern of cytokines, is
generally considered immunosuppressive. It inhibits IL-6
secretion by activated macrophages but not by Th2 lym-
phocytes [33]. In the present work, IL-10 was overpro-
duced by patients'lymphocyte cultures whereas their IL-6
IL-6 production Figure 3
IL-6 production. PBL and TIL from 17 NPC patients and PBL from 17 controls were cultured at a concentration of 2 × 106 
cells/ml in the presence of PWM at 1:200 dilution for 12 days. Culture supernatants were collected and assayed for IL-6.BMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
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levels were similar to controls, showing no signs of inhi-
bition by IL-10. This points to Th2 lymphocytes rather
than activated macrophages as the main source of IL-6 in
this system. The increased ability of patients lymphocytes
to produce IL-10 is compatible with the lack of CTL
activity.
Cultures of tumor infiltrating lymphocytes secreted signif-
icantly higher amounts of IgM and IgG than the PBL of
either patients or controls in good agreement with the
increased levels of IL-2 and IL-10, since these cytokines are
involved in B cell activation and enhance immunoglobu-
lin synthesis [23,25]. No significant correlations between
cytokine production and IgA secretion were found, in line
with the preferential enhancing effect of IL-2 and IL-10 on
IgM and IgG synthesis [23].
In an attempt to see whether the observed differences in
cytokine and immunoglobulin production between
patients and controls or between PBL and TIL of patients
could be due to differences in the composition of individ-
ual lymphocyte preparations, we performed an immu-
nophenotypic analysis of each lymphocyte preparation.
As shown in the results, the only significant changes in the
proportions of lymphocyte subsets between patients and
controls were observed in the CD8 subpopulation which
showed an increase in patients PBL and TIL. On the other
hand, the CD4 subset showed a significant decrease in
TIL. Such differences in lymphocyte subpopulations are
not expected to produce the changes in cytokine and
immunoglobulin production observed here, since CD4
lymphocytes are well known for being the main source of
IL-2 and IL-10, and for their ability to stimulate immu-
noglobulin synthesis [34].
Recently, CD4+ lymphocyte populations have been
shown to be more heterogeneous and complex than pre-
viously thought [35] and new subsets of T regulatory cells
IgM production Figure 4
IgM production. PBL and TIL from 17 NPC patients and PBL from 17 controls were cultured at a concentration of 2 × 106 
cells/ml in the presence of PWM at 1:200 dilution for 12 days. Culture supernatants were collected and assayed for IgM.BMC Cancer 2004, 4:68 http://www.biomedcentral.com/1471-2407/4/68
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(Tr) with immunosuppressive activities have been identi-
fied. Tr cells have been suggested to play a key role in the
evasion from immune-mediated clearance of microorgan-
isms and tumors [36]. It has also been reported that IL-10-
producing Tr1 cells dominate the immune response to
LMP1 in EBV seropositive subjects [36]. Since LMP1 is
expressed in NPC tumors, it would be tempting to specu-
late that the increase in IL-10 production by TIL would
correspond to an increase in Tr1 cells in the correspond-
ing NPC tumors. In this respect, Hodgkin lymphoma
infiltrating lymphocytes have been shown to contain large
populations of both Tr1 and CD4+CD25+ regulatory T
cells [37], and it would be interesting to see whether a
similar situation occurs in NPC.
Conclusion
In conclusion, our data point to the possibility of an
imbalance in immunoregulatory interleukin production
in NPC patients. Their lymphocytes, especially those infil-
trating the tumors, showed in particular a high propensity
to produce IL-10 following mitogenic stimulation in vitro.
Overproduction of this pleiotropic cytokine may lead to a
discrepancy between humoral and cellular immune
responses similar to that seen in NPC. The relevance of the
present observations to the in vivo situation is not yet
established and warrants further investigations.
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